- Current report filing (8-K)
16 January 2010 - 8:07AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 11, 2010
Idenix Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
|
|
Delaware
|
|
000-49839
|
|
45-0478605
|
|
(State or Other Jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
|
of Incorporation
|
|
File Number)
|
|
Identification No.)
|
|
|
|
|
|
60 Hampshire Street
|
|
|
|
Cambridge, MA
|
|
02139
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code:
(617) 995-9800
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (
see
General
Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers.
On January 11, 2010, Pamela Thomas-Graham notified Idenix Pharmaceuticals, Inc. (“Idenix”
or the “Company”) that she is voluntarily resigning from the Board of Directors, effective as
of January 11, 2010. Ms. Thomas-Graham has been a director of Idenix since 2005 and was
recently named Chief Talent, Branding and Communications Officer of Credit Suisse and a member
of the Executive Board of Credit Suisse.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
Idenix Pharmaceuticals, Inc.
|
|
|
Date: January 15, 2010
|
By:
|
/s/ John F. Weidenbruch
|
|
|
|
|
Name:
|
John F. Weidenbruch
|
|
|
|
|
Title:
|
Executive Vice President and General Counsel
|
|
|
|
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jun 2024 to Jul 2024
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jul 2023 to Jul 2024
